“Biocon is likely to sell a portion of its 69.99 percent stake in Syngene, sources have told CNBC-TV18.” Link
Biocon have mentioned in the past that, they would fund the Viatris deal with debt & equity commitments. Seems like, they are now forced to sell their better business (Syngene) to fund comparatively inferior, cash burning business. (Biosimilars)
What are your thoughts, fellow investors & veterans?
| Subscribe To Our Free Newsletter |
